Because of the "soul bargaining" popular female director turned, her work ability is how strong? Below we will address this issue for some discussion, I hope that these contents can help friends in need.
"Have you long done your larger efforts?" "Every small crowd should not be discarded either." "I do feel a little sad that all the previous efforts have been in vain." Earlier, the "700,000 dollar injection of high-priced drugs into Medicare" went on the hot list. Along with the popularity, there is also the National Health Insurance Administration negotiator Zhang Jinni, and her "classic words of price pressure".
Along with the new version of China's health insurance drug catalog landing style, from now on a number of patients into the regeneration. We note that just before New Year's Day, Zhang Jinni also smoothly according to the internship period, announced that the Fujian Provincial Health Insurance Bureau of the procurement of drugs and equipment Supervision Division Director.
The "high-priced drug" mentioned above, called sodium norethindrone injection, is the world's first treatment for spinal muscular atrophy (SMA), a rare disease with a prevalence rate of about 1/6,000 to 1/10,000 among newborn babies in China, and about 330,000 patients at this stage. It can cause relatively severe muscle stiffness and can even be fatal without medical treatment.
When it came into China in 2019, the price tag for a single injection of sodium nociceptin was more than 699,700 yuan, and patients had to inject four injections in the first 63 days, and one every four months toward the end, for a lifetime of medication.
November 2021, through the health insurance unit eight rounds of price bargaining, nosinafosan sodium injection price finally to less than 33,000 yuan per injection price volume. Negotiator of the National Health Insurance Bureau, Fujian Provincial Health Insurance Bureau of drug and equipment procurement and supervision department director Zhang Jinni also due to the "life pressure price", burst the Internet.
In the bargaining spot, the first round of prices, the company came up with a bottle of 53,680 yuan. "Expect the company to take out a more sincere price ...... If this drug will enter the national health insurance catalog, with the size of China's population, the confidence of China's government departments for the patient service program, it is difficult to find out that kind of sales market."
After several rounds of discussions, Zhang Jinni is still not satisfied with the price: "I firmly believe that the company feels particularly painful, but there is a certain spacing away from the fact that we can talk further." "Whether you have long done your best to a greater effort?" "Are you sure you have done your best?" Jinny Zhang kept negotiating the price with the company's negotiators. She added: "Every small group of people should not be discarded either." "I don't think tricks are practical for drugs at these kinds of prices."
After the fifth off-the-record deliberation, the treatment implies came up with a price of $37,800 for a bottle. Zhang Jinni smiled and said, "It's so hard for everyone at the negotiating table to be so low as a bidder." But against the moral bottom line of the price, the main demonstrated a decisive uncompromising mentality.
The company carried out the seventh negotiation after the price dropped to 34,020 yuan, Zhang Jinni's response was: "Feeling that the efforts of the front are in vain, I do a little sad." Through the bargaining team's group discussion, Zhang Jinni arrived at a price of 33,000 yuan, the company means the eighth time away from the discussion to determine the price. An hour and a half of long negotiation, accompanied by the word "volume", finally the perfect ending. A bottle of medicine sold for more than 20,000 yuan less than the initial price.
January 1, 2022, the new version of China's health insurance drug catalog landing style. On that day both Beijing, Shanghai, Guangdong, Zhejiang, Shandong and other 11 provinces and districts of the medical institutions of nearly 20 patients, admitted to the nociceptin sodium injection medical treatment.
Previously, the party group of China **** Fujian Provincial Bureau of Medical Protection announced personnel adjustment notice: the decision was made, Zhang Jinni friend of my Bureau of Medical Device Acquisition Supervision Division director of a one-year internship period has been completed, after the evaluation of the standard, is given to announce the inauguration.
Published reports indicate that Zhang Jinni graduated from Fujian Medical University in clinical medicine, served as director of the office of the Fujian Provincial Medical Insurance Fund Management Center. in June 2016, she served as deputy director of the Fujian Provincial Medical Insurance Bureau of the acquisition of medical devices Supervision and Regulation Department (internship period of one year, presiding over the work), October 2020 was promoted to the director of the Department (internship period of one year). One of the job responsibilities of the Medical Device Acquisition Supervision Division happens to be "institutional drug and medical consumables price negotiation".